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Abstract
Selective IgA deficiency is defined as absolute or partial when serum IgA level is < 7 mg/dl or 2 SD below normal for
age, respectively. Few data are available on partial selective IgA deficiency, as probably most children with low serum
IgA are seldom referred to a specialist clinic in common pediatric practice. The aim of our study was to better define
the profile of both symptomatic forms and their clinical outcome in a pediatric immunology setting. Thus, clinical and
immunological data from 103 symptomatic patients with selective IgA deficiency (53 absolute and 50 partial), 4–
18 years of age, were collected at diagnosis and 80 patients (44 absolute and 36 partial) were monitored for a mean
period of 5 years. Also, the prevalence of TNFRSF13B mutations has been assessed in 56 patients. The most common
clinical features were infections (86/103; 83%), allergy (39/103; 38%), and autoimmunity (13/103; 13%). No signif-
icative differences were observed between absolute and partial selective IgA deficiency patients. However, a signifi-
cative difference in the rate of IgA normalization between partial and absolute selective IgA deficiency patients (33 vs
9%, p = 0.01) was detected. Furthermore, a lower incidence of infections was associated to a normalization reversal
compared to a final absolute or partial defect status (12 vs 53 and 64% respectively, p < 0.01).
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Conclusions: Regardless of a diagnosis of absolute or partial defect, monitoring of symptomatic patients with selective IgA
deficiency is recommended overtime for prompt identification and treatment of associated diseases. Further, diagnostic workup
protocols should be revisited in children with IgA deficiency.
What is Known:
● Selective IgA Deficiency is the most common primary immunodeficiency and is usually asymptomatic.
● Symptomatic pediatric patients with selective IgA deficiency mostly suffer with respiratory and gastrointestinal infections.
What is New:
● Symptomatic children with partial IgA defect may have similar clinical, immunological, and genetic features than symptomatic children with absolute
IgA deficiency.
● Symptomatic children with partial IgA deficiency deserve accurate monitoring for associated diseases as per children with absolute IgA deficiency.
Keywords TNFRSF13B . Antibody deficiency . Primary immunodeficiency . Recurrent respiratory infections
Abbreviations
SIGAD Selective IgA deficiency
PID Primary immunodeficiency disease
TACI Transmembrane activator and calcium modulator
and cyclophilin ligand interactor
CVID Common variable immunodeficiency
aSIGAD Absolute selective IgA deficiency
pSIGAD Partial selective IgA deficiency
Introduction
Selective IgA deficiency (SIGAD) is the most common primary
immunodeficiency disease (PID) that occurs in 1:300–1:700
individuals [5, 7, 42, 44]. This antibody defect is characterized
by decreased or absent serum IgA level with normal IgG and
IgM values in patients older than 4 years of age [48]. SIGAD is
usually defined “absolute” when serum IgA level is less than
7 mg/dl and “partial” when IgA level is 2 SD below normal for
age [48].
The pathogenesis of SIGAD is still unknown, but a defect
in class switch recombination and mutation of some genes
have been related to the disease. Particularly, polymorphisms
of the HLA system, variants of genes known to regulate IgA
production and mutations in the gene encoding transmem-
brane activator and calcium modulator and cyclophilin ligand
interactor (TACI), the TNFRSF13B gene, have been observed
[1, 8–10, 42, 46]. The identification of TNFRSF13B gene
mutations in other primary immunodeficiencies, such as com-
mon variable immunodeficiency (CVID) [35, 48] and tran-
sient hypogammaglobulinemia of infancy [6], supports the
idea of a common relationship [48].
SIGAD is often asymptomatic and the diagnosis is some-
times incidental [48]. Symptomatic patients represent
approximately 10–15% of all PID [30, 42] and 10–35% of
all SIGAD [47, 48] with a higher prevalence in males [7]. In
children, recurrent infections are the major manifestations that
can lead to an immunological investigation [11, 46].
Infections, which usually involve the respiratory, urinary,
and gastrointestinal tracts, are commonly caused by
Haemophilus influenzae, Streptococcus pneumoniae,
Giardia lamblia, Helicobacter pylori, Salmonella, or
Campylobacter [2, 11, 13, 21, 33, 37, 48]. Rarely, disseminat-
ed infections have been reported [7].
Allergic diseases are also frequent [2, 43, 46] andmay be the
first and/or the sole feature. Several studies have reported a high
incidence of allergy presumably due to the loss of the capacity
to block the allergen absorption with further sensitization and
development of allergic disease in these patients [43, 47].
A variety of autoimmune diseases including hemato-
logic disorders, i.e., neutropenia and thrombocytopenia;
gastrointestinal disorders, i.e., coeliac disease, Crohn
disease, ulcerative colitis, and primary biliary cirrhosis;
lupus-like illnesses; arthritis; autoimmune thyroiditis;
and type 1 diabetes [5, 7, 22, 44, 45] have been observed
in SIGAD patients, predominantly in adult women [11,
13, 20, 48]. Several mechanisms have been postulated to
be involved in the autoimmune pathogenesis such as the
absence of secretory IgA, which could enable the transi-
tion of environmental antigens and the formation of auto-
antibodies by molecular mimicry with self-antigens, and
the presence of abnormal Treg cell levels, which could
lead to the breakdown of immune tolerance [46].
Furthermore, during the natural course of the disease, ma-
lignancies, i.e., gastric carcinoma and lymphoproliferative
syndrome, may occur with age [47, 48].
Most SIGAD patients have a good prognosis and some-
times IgA levels may normalize over time. Conversely, 5%
of these patients may represent part of a phenotype of a more
severe disease and likely progress to CVID disease [4, 7, 22,
44, 45, 48]. Symptomatic children with partial IgA deficien-
cy are commonly considered with a mild variant of SIGAD
that rarely deserves referral to a specialist clinic. Thus, there
is a general attitude to focus both scientific papers and PID
registries on the absolute form and scarce data on
symptomatic patients with partial IgA deficiency are
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available. This study was undertaken to draw the profile and
clinical outcome of both forms in patients evaluated in three
pediatric immunology settings.
Methods
Patients with absolute and partial IgA deficiency were
identified during routine assessment for recurrent infec-
tions and/or allergy and/or autoimmunity and enrolled at
the Pediatric Immunopathology and Allergology Unit of
Policlinico of Tor Vergata in Rome, at the Department of
Pediatrics of Malpighi Hospital in Bologna, and at the
Pediatric Immunology Center of Federico II University
in Naples. Clinical and immunological features of 103
SIGAD patients (57 males and 46 females), 53 (31
males and 22 females) with absolute IgA deficiency
(aSIGAD), and 50 (26 males and 24 females) with par-
tial IgA deficiency (pSIGAD) were analyzed. According
to the diagnostic criteria of the Italian Primary
Immunodeficiency Network, symptomatic patients with
an absolute defect matched the following criteria: (a)
age ≥ 4 years, (b) serum IgA levels <7 mg/dl, (c) normal
serum IgG and IgM levels. On the other hand, we clas-
sified symptomatic patients with a partial defect when
the following criteria were matched: (a) age ≥ 4 years,
(b) IgA levels 2 SD below normal for age, (c) normal
serum IgG and IgM levels. All symptomatic SIGAD
patients had normal values of T and B lymphocyte sub-
sets as detected by FACS and compared to age-
appropriate values [12, 39], specific IgG antibody re-
sponse to Haemophilus influenzae, tetanus, and/or
Streptococcus pneumoniae as analyzed by ELISA
(Binding Site, Birmingham, England) and IgG subclasses
assay by radial immunodiffusion. Also, secondary causes
of hypogammaglobulinemia were excluded.
Clinical and immunological data were collected at en-
rollment and every 6–12 months according to common
clinical practice for a total mean follow-up period of
5 years. Immunological data included Ig quantification by
nephelometry and antinuclear antibody (ANA).
Genetic analysis for TNFRSF13B mutation was performed
in 56 patients (32 aSIGAD and 24 pSIGAD).
The institutional review board approved the study and
informed consent was obtained at diagnosis from all indi-
vidual participants included in the study.
Statistical analysis
Clinical and immunological data of patients with absolute
vs partial IgA deficiency were compared using Fisher’s
exact test and chi-square test. A P value < 0.05 was con-
sidered as significant.
Results
Clinical and immunological features of 103 patients
at diagnosis
Our cohort of 103 SIGAD patients was composed of 53
aSIGAD and 50 pSIGAD.Mean age was of 7 years (age range
4–18 years). As reported in Table 1, a positive family history
for PID was present in the family of 20 (19%) patients with a
higher incidence of SIGAD (90%), and of unclassified prima-
ry immunodeficiency and common variable immunodeficien-
cy in 15 and 10%, respectively. Allergy and autoimmunity
characterized the family history of 47 (46%) and 31 (30%)
patients, respectively. Autoimmune thyroiditis and coeliac
disease were the major autoimmune diseases and were ob-
served in the family of 10 (32%) and 8 (26%) patients, respec-
tively. A comparison of family history between aSIGAD and
pSIGAD groups showed no significative difference.
As reported in Table 2, clinical features could be grouped
into four categories: infections, allergy, autoimmunity, and
other conditions. Infections were observed in 86/103 (83%)
patients, mainly involving the respiratory tract (82/86, 95%).
Upper respiratory tract infections affected 56/82 (68%) pa-
tients, lower respiratory tract infections involved only 5/82
(6%) patients, and the simultaneous occurrence of upper and
lower respiratory tract infections was found in 21/82 (26%)
patients. Gastrointestinal infections represented the second
most frequent infections occurring in 16/86 (19%) patients.
The main gastrointestinal pathogen was represented by
Giardia lamblia, found in 6/16 (38%) patients. Allergic
diseases were reported in 39/103 (38%) patients with rhinitis
in 19/39 (49%), atopic dermatitis in 13/39 (33%), asthma in
11/39 (28%), and conjunctivit is in 10/39 (26%).
Autoimmunity was observed in 13/103 (13%) SIGAD pa-
tients with a higher incidence of coeliac disease in 8/13
(62%) whereas autoimmune thyroiditis and idiopathic juve-
nile arthritis were found in 3/13 (23%) and in 2/13 (15%)
patients, respectively. Among the other conditions, in 9/103
patients (9%), recurrent abdominal pain (56%) and oral
aphthosis (22%) were reported. At diagnosis, malignancy
was never observed in any group. As detailed in Table 2, no
significative differences emerged in the clinical picture of
aSIGAD vs pSIGAD. Of note, when in both cohorts we eval-
uated the impact of age (< 10 years vs > 10 years) on all de-
scribed clinical categories, no significative differences were
found (data not shown).
When antinuclear antibodies (ANA) were analyzed in all
SIGAD patients, among those 16/103 (16%) who tested
positive, only one ANA+ pSIGAD patient suffered from idi-
opathic juvenile arthritis (data not shown).
The analysis for TNFRSF13B gene was performed in 56
patients (32 aSIGAD and 24 pSIGAD), and 11/56 (20%), 4
aSIGAD (13%) and 7 pSIGAD (29%), carried a variant
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(Table 3). The heterozygous C104R mutation was identified
in four patients and three of them had a partial SIGAD.
Among TACI-mutated patients, a positive family history for
autoimmune diseases was observed in 2/4 (50%) aSIGAD and
in 5/7 (71%) pSIGAD. Autoimmune manifestations were
present in two patients at diagnosis and maintained at fol-
low-up. Both had a partial defect, were heterozygous for
C104R, and suffering with coeliac disease, associated to au-
toimmune thyroiditis in one of them. Antinuclear antibodies
were detected in 1/11 (9%) TACI-mutated patients; no auto-
immune disease was ever observed in this pSIGAD patient.
Again, no significative differences appeared in the group of
aSIGAD vs pSIGAD patients.
Clinical and immunological features of 80 patients
at follow-up
In our study, we monitored 80 patients (44 aSIGAD and 36
pSIGAD, mean age 12 years) for a mean period of 5 years. As
reported in Fig. 1, IgA values changed overtime. Particularly,
29/44 (66%) patients with initial diagnosis of aSIGAD
retained the absolute defect, conversely 11/44 (25%) shifted
to a partial SIGAD defect, and 4/44 (9%) spontaneously
reached normal IgA values. In patients with an initial diagno-
sis of pSIGAD, we observed a persistence of partial IgA de-
ficiency in 17/36 (47%), whereas 7/36 (19%) patients evolved
to an absolute defect and 12/36 (33%) to IgA normalization.
Our data showed that the chance for IgA normalization was
higher for pSIGAD than that for aSIGAD patients (33 vs 9%,
p = 0.01) (Fig. 1). Mean age of normalization was 9 years for
both groups.
At final follow-up, absolute and partial defects were ob-
served in 36/80 (45%) and 28/80 (35%) patients, respectively,
whereas 16/80 (20%) patients had reversed to normal IgA
values. Clinical data of patients with aSIGAD, pSIGAD, and
normalization reversal at follow-up are reported in Fig. 2.
Particularly, infections of the respiratory and gastrointestinal
tract remained the most common clinical features in aSIGAD
(19/36; 53%) and in pSIGAD (18/28; 64%), whereas
normalization of IgA values was associated to a significative
lower rate of infections (2/16; 12%) compared to aSIGAD
(p = 0.007) and pSIGAD (p = 0.001).
Allergy represented the second most frequent clinical con-
dition with an irrelevant distribution from 25 to 38% in the
different groups of aSIGAD, pSIGAD, and patients with nor-
malization of IgA values. In all groups, rhinitis was
predominant, followed by conjunctivitis and asthma.
Autoimmune diseases, such as coeliac disease, autoimmune
thyroiditis, and diabetes, were observed in 3/36 (8%) aSIGAD
and in 5/28 (18%) pSIGAD patients. Two of them from each
group developed autoimmunity with time. Conversely, no au-
toimmune disease was ever observed in patients who normal-
ized IgA levels. Furthermore, other gastrointestinal conditions,
such as recurrent abdominal pain and aphthosis, were observed
in 2/36 (5%) aSIGAD, 4/28 (14%) pSIGAD, and 3/16 (18%)
patients with normalization of IgA values. The incidence of
autoimmunity and other gastrointestinal conditions was not
significant among all groups; also, no malignancies were ob-
served at follow-up. Again, when both cohorts were stratified
according to age (< 10 years vs > 10 years) for all described
clinical categories, no significative differences were found (da-
ta not shown).
Table 1 Family history for
primary immunodeficiency,
allergy, and/or autoimmunity of
103 patients with selective IgA
deficiency (SIGAD)
SIGAD aSIGAD pSIGAD p value
Primary immunodeficiency (PID) 20/103 (19%) 10/103 (10%) 10/103 (10%) 1.0
Selective IgA deficiency (SIGAD) 18/20 (90%) 9/10 (90%) 9/10 (90%)
Unclassified PID 3/20 (15%) 2/10 (20%) 1/10 (10%)
Common variable immunodeficiency (CVID) 2/20 (10%) 0/10 (0%) 2/10 (20%)
Allergy 47/103 (46%) 20/103 (19%) 27/103 (26%) 0.11
Rhinitis 33/47 (70%) 15/20 (75%) 18/27 (66%)
Conjunctivitis 19/47 (40%) 14/20 (70%) 5/27 (19%)
Asthma 12/47 (26%) 5/20 (25%) 7/27 (26%)
Not defined respiratory allergy 4/47 (9%) 2/20 (10%) 2/27 (7%)
Other 8/47 (17%) 3/20 (15%) 5/27 (19%)
Autoimmunity 31/103 (30%) 16/103 (16%) 15/103 (15%) 1.0
Autoimmune thyroiditis 10/31 (32%) 5/16 (31%) 5/15 (33%)
Coeliac disease (CD) 8/31 (26%) 5/16 (31%) 3/15 (20%)
Type I diabetes mellitus (DM) 7/31 (23%) 2/16 (12%) 5/15 (33%)
Autoimmune cytopenias 4/31 (13%) 1/16 (6%) 3/15 (20%)
Arthritis 2/31 (6%) 1/16 (6%) 1/15 (7%)
Other 7/31 (23%) 3/16 (19%) 4/15 (27%)
The percentages total more than 100% because some patients had more than one disease in family history
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Table 2 Clinical manifestations
of 103 patients with selective IgA
deficiency (SIGAD) at diagnosis
Clinical manifestations SIGAD aSIGAD pSIGAD p value
Infections 86/103 (83%) 44/53 (83%) 42/50 (84%) 1.0
Respiratory tract infections 82/86 (95%) 41/44 (93%) 41/42 (98%)
URTI 56/82 (68%) 25/41 (61%) 31/41 (76%)
LRTI 5/82 (6%) 3/41 (7%) 2/41 (5%)
URTI+LRTI 21/82 (26%) 13/41 (32%) 8/41 (20%)
Gastrointestinal infections 16/86 (19%) 6/44 (14%) 10/42 (24%)
Giardia infections 6/16 (38%) 2/6 (33%) 4/10 (40%)
Urinary tract infections (UTI) 5/86 (6%) 1/44 (2%) 4/42 (10%)
Fever 1/86 (1%) 1/44 (2%) 0/42 (0%)
HSVand VZV infections 3/86 (3%) 1/44 (2%) 2/42 (5%)
Candidiasis 2/86 (2%) 0/44 (0%) 2/42 (5%)
Allergy 39/103 (38%) 19/53 (36%) 20/50 (40%) 0.68
Rhinitis 19/39 (49%) 8/19 (42%) 11/20 (55%)
Atopic dermatitis 13/39 (33%) 3/19 (16%) 10/20 (50%)
Asthma 11/39 (28%) 5/19 (26%) 6/20 (30%)
Conjunctivitis 10/39 (26%) 7/19 (37%) 3/20 (15%)
Other 10/39 (26%) 6/19 (32%) 4/20 (20%)
Autoimmunity 13/103 (13%) 4/53 (8%) 9/50 (18%) 0.14
Coeliac disease (CD) 8/13 (62%) 3/4 (75%) 5/9 (56%)
Autoimmune thyroiditis 3/13 (23%) 1/4 (25%) 2/9 (22%)
Idiopathic juvenile arthritis (IJA) 2/13 (15%) 0/4 (0%) 2/9 (22%)
Type I diabetes mellitus (DM) 1/13 (8%) 1/4 (25%) 0/9 (0%)
Other 1/13 (8%) 0/4 (0%) 1/9 (11%)
Other conditions 9/103 (9%) 4/53 (8%) 5/50 (10%) 0.73
Recurrent abdominal pain 5/9 (56%) 2/4 (50%) 3/5 (60%)
Aphthosis 2/9 (22%) 1/4 (25%) 1/5 (20%)
Other 3/9 (33%) 1/4 (25%) 2/5 (40%)
Malignancy 0/103 (0%) 0/53 (0%) 0/50 (0%) 1.0
The percentages total more than 100% because some patients had more than one type of clinical manifestation
URTI upper respiratory tract infections, LRTI lower respiratory tract infections
Table 3 Autoimmunity in 11
SIGAD patients with
TNFRSF13B gene mutation at
Patient Sex Age Mutation Family history for
autoimmunity
Autoimmunity at
diagnosis
Autoimmunity at
follow-up
ANA
aSIGAD
Pt.1 M 12 C104 Yes No No Neg
Pt.2 F 14 C66X No No No Neg
Pt.3 F 6 C193X Yes No No Neg
Pt.4 M 8 G190A No No No Neg
pSIGAD
Pt.1 M 17 fsX80 Yes No No Neg
Pt.2 M 7 C104R Yes CD CD Neg
Pt.3 F 17 C104R Yes CD, AT CD, AT Neg
Pt.4 F 4 R202H No No No Neg
Pt.5 M 12 C104R No No No Neg
Pt.6 F 12 I87N Yes No No Pos
Pt.7 F 10 fs220X Yes No No Neg
CD coeliac disease, AT autoimmune thyroiditis, Neg negative, Pos positive
aSIGAD vs pSIGAD p = 0.17
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Discussion
Selective IgA deficiency (SIGAD) is the most common pri-
mary immunodeficiency disorder, with a worldwide incidence
ranging from 1:300 to 1:600 individuals. The incidence is
higher in Caucasians; however, community settings and defi-
nition criteria for IgA deficiency account for the different rates
reported so far. To limit the variables that affect epidemiologic
data, we focused on symptomatic > 4-year old children re-
ferred to our specialty clinics who followed an established
routine protocol that led to the identification of low IgAvalues
with the exclusion of other immunological abnormalities and
secondary causes.
Several studies have provided a clinical and immunological
characterization of patients with an absolute defect (aSIGAD)
as defined when serum IgA level is < 7 mg/dl, but few data are
available on partial IgA deficiency (pSIGAD) as defined when
serum IgA level is 2 SD below normal for age. In fact,
pSIGAD commonly goes unnoticed or it is considered as a
mild variant of SIGAD with a better clinical outcome. In our
study, clinical, immunological, and genetic features of
aSIGAD versus pSIGAD patients indicate that both condi-
tions deserve a proper evaluation and regular monitoring.
A positive family history is the most significant warning
sign to identify an immunodeficiency [36]. It has been esti-
mated that about 20–25% of SIGAD patients have a family
history of PID [7]. We observed PID in the family members of
19% of SIGAD patients with equal distribution between
aSIGAD and pSIGAD cohorts. Conversely, scarce data are
available on the family history for allergy and/or autoimmu-
nity in children with SIGAD. In our SIGAD patients, 46% of
them had a family history for allergy disorders and 30% for
autoimmunity. Although no significant differences were
found in the frequency and type of allergy or autoimmune
disorders in the family of our aSIGAD vs pSIGAD cohorts,
the proportion of SIGAD family members with autoimmunity
is relevant. Therefore, considering their lower frequency in the
general population, awareness among healthcare physicians
should be raised in the presence of parents/family members
who suffer of a variety of immune dysregulations for early
counseling.
Patients with SIGAD show a heterogeneous clinical phe-
notype, from an asymptomatic state to a range of associated
manifestations that can be categorized into infections, allergy,
autoimmunity, and malignancy. In our study, at diagnosis,
symptomatic children with aSIGAD shared the same clinical
profile of symptomatic pSIGAD patients. Indeed, infectious
diseases, predominantly respiratory and gastrointestinal tract
infections, are the most common clinical manifestations of
symptomatic SIGAD children in 40–90% of cases [3, 5].
Conversely, a lower incidence of infections is observed in
adult cohorts of SIGAD individuals [27, 32]. Our results
demonstrate that not only aSIGAD but also pSIGAD children
show a high frequency of infections as previously reported [3,
6] since we detected a frequency of 93–98% for respiratory
infections and of 14–24% for gastrointestinal infections. Thus,
the function and the quantity of IgA in mucosal immunity,
especially in the defense against pathogens harboring the re-
spiratory and the gastrointestinal tract, seem critical in the
pediatric age.
Allergies and autoimmune disorders may characterize
the clinical picture of SIGAD patients and may be the first
and/or sole clinical manifestation, too. The prevalence of
allergy and autoimmune diseases in SIGAD patients
mostly ranges from 25 to 50% and from 5 to 30%, respec-
tively [13, 14, 21, 34, 37, 42, 43, 47]. In our SIGAD
cohorts, the prevalence of allergic disorders was of 38%
which fits previous estimates on similar cohorts and the
no t ion tha t a l l e rgy and au to immuni ty may be
overexpressed in SIGAD patients than in the general
population [6]. In fact, the frequency of autoimmune dis-
orders in our aSIGAD and pSIGAD patients, 8 and 18%
respectively, was higher than the 3–5% reported in
Western general population. Further, the high prevalence
of IgA deficiency among patients initially diagnosed with
autoimmune disorders is also true, pointing to the protec-
tive role of IgA against autoimmunity with a strong ge-
netic and environmental influence. The incidence of auto-
immunity has been demonstrated to be higher in the adult
SIGAD population [32] compared to the pediatric SIGAD
cohort supporting the assertion that the occurrence of au-
toimmune diseases comes with age [46, 47].
Several studies have suggested that SIGAD patients have
an increased risk of neoplasia, such as lymphoma and gastric
cancer, especially at older ages [28, 42, 46]. Other neoplasia
identified in SIGAD patients are carcinoma of the colon,
ovarian cancer, lymphosarcoma, melanoma, and thymoma
[4, 46]. Ludvigssonn et al. found a 31% increased relative risk
of cancer in a cohort of absolute IgA-deficient adults. In our
study, no malignancy emerged in both SIGAD variants, in
accordance with previous reports that showed the low preva-
lence of malignancy in children with SIGAD [46, 48].
Although sera from SIGAD patients may contain antinu-
clear antibodies, the relevance of autoantibody production in
the absence of clinical autoimmunity needs to be elucidated
with a rigorous long-term follow-up.
The pathogenesis of IgA deficiency is still unknown but a
failure of B cell differentiation with abnormal cytokine release
and/or cellular signaling unbalance as well as increased apo-
ptosis are reported as major causative mechanisms as per
CVID. Both CVID and SIGAD share clinical manifestations
and are identified in family members. Progression to CVID
may occur in SIGAD patients. The hypothesis of a shared
genetics that might include several genes is intriguing.
Several susceptibility loci have been described for IgA defi-
ciency [1, 15, 16, 19, 23, 29, 31, 46]. A recent genome-wide
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association study meta-analysis identified common variants of
PVT1, ATG13-AMBRA1, AHI1, and CLEC16A associated
with SIGAD [8].
The role of TACI in B cell proliferation, isotype switching,
antibody responses, and central tolerance has been previously
demonstrated [17]. TNFRSF13B gene mutation has been re-
ported in approximately 10% of CVID patients and heterozy-
gous variants found to be associated with autoimmune and
lymphoproliferative disorders. Conversely, in IgA-deficient
patients, although TNFRSF13B mutations have been variably
detected according to the different cohorts [17, 26], as well as
in about 2% of healthy subjects, they do not seem to play a
primary role but do act as modifiers and co-participants of the
disease [18]. In accordance with the study by Pulvirenti et al.
[35], we found a relative higher frequency of TNFRSF13B
mutations (13%) in our cohort of symptomatic aSIGAD pa-
tients and even more in those with partial defect (29%). In our
TACI-mutated cohort, eight different genetic alterations were
Fig. 2 Distribution of patients
with selective IgA deficiency
(SIGAD) in relation to clinical
features at follow-up. Red bars
refer to patients with an absolute
defect, lilac bars to patients with
partial IgA defect, and green bars
to normalized patients. The
asterisk indicates a significant
difference (p < 0.05) between the
two analyzed groups
Fig. 1 The progress of patients
with selective IgA deficiency
(SIGAD) over a 5-year period.
Red bars refer to patients with an
absolute defect, lilac bars to
patients with partial IgA defect,
and green bars to normalized
patients. The asterisk indicates a
significant difference (p < 0.05)
between the two analyzed groups
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observed, but monoallelic C104R was identified more fre-
quently than non-C104Rmutations. However, the clinical sig-
nificance of TNFRSF13B variants in SIGAD patients is con-
troversial and the occurrence of autoimmunity may vary ac-
cording to a combination of several demographic, genetic, and
environmental components [6]. Also, careful monitoring of
family members might add valuable information on the break-
down of human immune system [18, 26, 38].
Currently, few studies with a long-term follow-up of
SIGAD patients are available. Several studies reported that
pediatric SIGAD patients may reach normal IgA values over
time [21, 41] and sometimes shift to a partial defect [21].
Normalization and evolution to a partial defect were both ob-
served in 28% of patients [25]. Also, in our 5-year follow-up
of 80 patients, IgAvalues may change over time. In detail, the
persistence of an absolute defect was observed in 66% of
aSIGAD, the shift to a partial defect in 25% of cases, and
normalization of IgA values occurred in 9% of patients.
Few studies have characterized pSIGAD patients over time
[24, 40]. In our cohort, the partial defect was maintained in
47% of patients and shifted to absolute in 19%. Normalization
of IgA levels was significantly more frequent in pSIGAD than
in aSIGAD (33 vs 9%, p = 0.01), and it occurred at a mean age
of 9 years for both forms of SIGAD.
Interestingly, patients who retained an absolute or partial
IgA defect continued to present symptoms, regardless of their
initial absolute or partial IgA deficiency. Conversely,
normalization of IgA levels led to a significant reduction of
infectious manifestations. Since autoimmunity comes with
age in both PID and non-PID patients, extensive studies on
partial and absolute SIGAD adults could aid to clarify the
natural history of the disease and might envisage the revision
of diagnostic criteria to improve preventive and therapeutic
management of these patients. Yet, the strong association of
SIGAD with other immune-mediated diseases and the high
prevalence of family members with different immune pathol-
ogies would imply that SIGAD is often a warning sign of a
more complex disorder.
The lack of homogeneous cohorts renders critical any data
comparisons from the different sources; however, the notion
that pediatric IgA deficiency may be a reversible or progres-
sive disorder is clear. Our data suggest that a negative family
history for PID, absence of autoimmune diseases, and fewer
infections seem to predict a benign condition. Although we
might provide only a partial view of an evolving process in
which several environmental and genetic factors are involved,
the role of the different actors of the disease, including
TNFRSF13B, needs to be further elucidated.
In conclusion, a regular long-term follow-up of patients
with IgA deficiency is required for early diagnosis of
associated diseases and to implement workup protocols.
Further, the impact of partial IgA deficiency should be mon-
itored in clinical practice for a more comprehensive
examination of the complex interplay that regulates the spe-
cialized role of IgA.
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